James R. Baker, Jr., MD - CEO

Dr. Baker is the inventor of the platform technology, founder of NanoBio and an internationally recognized expert in immunology and nanotechnology.  Dr. Baker invented the NanoStat technology at the University of Michigan, where he is the Ruth Dow Doan Professor of Medicine and Head of Allergy and Immunology at the Medical School.  As the Director of the University of Michigan Nanotechnology Institute, Dr. Baker leads a multidisciplinary team of 30 scientists focused on the use of nanotechnology in biomedical applications.  He is one of three editors of the National Nanotechnology Initiative’s Research Directives, and a member of the Nanotechnology for Medicine and Biology study section at National Institutes of Health (“NIH”).  Dr. Baker is a board-certified internist, allergist and immunologist, a member of American Board of Allergy and Immunology and a Fellow of the American College of Physicians. He is also a Fellow of the American Academy for the Advancement of Science.

David Peralta - Vice President, Chief Operating & Chief Financial Officer

Mr. Peralta joined NanoBio in February 2006, and is directly responsible for all of the company's business and finance-related activities.  Prior to joining the company, Mr. Peralta most recently served as vice president and chief financial officer for Arbortext, Inc., a venture-backed enterprise software company.  While at Arbortext, Mr. Peralta played a key role in transforming the company to a high-growth software business, which ultimately led to Arbortext being acquired in 2005 for $195 million in cash. Before joining Arbortext, Peralta served for six years as the chief financial officer of Mechanical Dynamics, Inc. (NASDAQ: MDII), a publicly-held software company.  Mr. Peralta directed all finance and investor relations activities at Mechanical Dynamics during the company's initial public offering in 1996, and up through the sale of the company in 2002. Mr. Peralta is a Certified Public Accountant in the State of Michigan.

Ali I. Fattom, PhD - Sr. Vice President Vaccine Research and Development

Dr. Fattom joined NanoBio in November 2010 with 25 years of experience in vaccine research and development. He initiated his career as a vaccinologist at The National Institutes of Health, where he helped develop several vaccines including Pneumococcus conjugate vaccine and headed the effort for developing a S. aureus vaccine. He later joined Univax Biologics to pursue the development of conjugate vaccines against bacterial infections including Staphylococci. Following the merger between Univax and North American Biologics to form Nabi Biopharmaceuticals, Dr. Fattom assumed responsibility for other research activities and served as Vice President of Research from 2003 to 2010. He earned a B. S. from The Hebrew University of Jerusalem, a M.S. in Microbiology from Tel-Aviv University, and a Ph.D. in Microbial Ecology from the Hebrew University of Jerusalem. From 1983-1986 he held an assistant professorship at Bir-Zeit University, West Bank. Dr. Fattom is author of over 50 peer reviewed publications, and holds more than 10 patents.

Lyou-fu Ma, PharmD, PhD – Sr. Vice President of Development

Dr. Ma has 17 years of experience in the pharmaceutical industry. Prior to joining NanoBio in July 2007, Dr. Ma was a Senior Director at Pfizer Global Research and Development where she held the position of Development Team Leader in the Pain Therapy Area. In this leadership role, she was responsible for setting the strategic and operational direction for numerous compounds in development and was the single point of accountability for each of her development teams. In her tenure with Pfizer she has also led early and late stage drug development teams in the Neurosciences, Inflammation and Cardiovascular therapeutic areas. Upon completion of graduate school, she joined the Pharmaceutics group at the Parke-Davis/Warner-Lambert facility in Morristown, NJ. She joined Janssen Research Technology Center (J & J) in Ann Arbor, Michigan in 1993, where she held the position of Senior Scientist and was responsible for formulation development, scale-up, manufacturing and early analytical testing of rapid-melt dosage forms.

Mary R. Flack, MD - Vice President Clinical Research

Dr. Flack has nearly 20 years of clinical research experience at the NIH and in the pharmaceutical industry.  Before joining NanoBio in 2002, Dr. Flack was Clinical Director of Endocrinology and Women’s Health Care at Pfizer (formerly Parke-Davis/Warner Lambert) where she was responsible for clinical development of pharmaceutical products for osteoporosis, hormone replacement therapy, fertility and contraception. She directed the completion of multiple clinical studies (Phases I-IV), leading to four approved NDA submissions, and has extensive experience with three different divisions of the FDA, including dermatology, endocrinology and reproductive health.

Stephen (Steve) Gracon, DVM– Vice President of Regulatory Affairs

Steve Gracon, joins NanoBio with 30 years experience in the pharmaceutical industry at Parke-Davis, Pfizer, Amgen and Baxter. Steve brings a diversity to NanoBio having spent 8 years in preclinical pathology and experimental toxicology, more than a decade in clinical research during which he lead the development of the tacrine (Cognex) the first drug approved for the treatment of Alzheimer’s disease before moving to Regulatory Affairs gaining both International and US Regulatory experience. Steve comes to NanoBio with a unique combination of experiences with small and large molecules and plasma derived products. He returns to Ann Arbor with great enthusiasm for the scientific community and the entrepreneurial spirit offered within the team at NanoBio.